skip to main content

Platform Trial Oncology — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

HardClinical Trials & StatisticsPlatform Trial OncologySCE Medical Oncology

A patient has advanced RET M918T-mutant medullary thyroid cancer requiring further systemic treatment after progression on cabozantinib. Which NHS treatment is supported by NICE TA1038?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: C — Use selpercatinib because prior cabozantinib satisfies the targeted-treatment requirement

TA1038 recommends selpercatinib for advanced RET-mutant medullary thyroid cancer requiring systemic treatment after cabozantinib or vandetanib; failure of both is not required. Medullary carcinoma is not treated as iodine-avid differentiated thyroid cancer. Lenvatinib is not the RET-mutant MTC recommendation, and the established need for systemic treatment makes surveillance inappropriate.

Reference: NICE TA1038: selpercatinib for previously treated advanced thyroid cancer with RET alterations. https://www.nice.org.uk/guidance/ta1038/chapter/1-Recommendations